ACTB is a clinical stage bio-therapeutics company, dedicated to developing and commercializing targeted oral cancer drugs in a variety of solid tumor indications.

Dr. Georg Nebgen and John R. Costantino hold seats on the board of directors. Dr. Bernard M. Peperstraete holds an observer seat.

ACT Biotech is based in San Francisco, CA

NGN Capital led a $10.5 million Series C financing of Medrium, Inc., a roll-up of medical billing practices.

Medrium offers outsourced billing services for high-volume, hospital-based physician practices primarily in the emergency medicine and radiology specialties. With dedicated resources and proprietary technology, Medrium provides several benefits to clients such as reduced error/rejection rates, faster reimbursement from payers, improved operational workflow, and sophisticated analytics for managing time per procedure. Medrium’s growth strategy involves completing acquisitions in key specialties or geographic regions in a manner that would take advantage of its existing technology and expertise.

John R. Costantino holds a seat on the board of directors and Loren A. Busby holds an observer seat.

Medrium is headquartered in Morristown, NJ.

www.medrium.com

NGN Capital led a $7.75 million Series B financing of Valtech Cardio, Ltd., a medical device company engaged in mitral valve repair using minimally invasive technology.

Currently, repair of the mitral valve requires open heart surgery. Valtech’s technology will allow for repair of the mitral valve via a minimally invasive procedure. Conversion of mitral valve repair to less invasive methods is expected to reduce the risk, duration and cost of such procedures and also considerably increase the pool of candidate patients, many of whom are otherwise clinically unsuitable for a traumatic open heart procedure.

Kenneth S. Abramowitz and Dr. Georg Nebgen hold seats on the board of directors and Noah J. Kroloff holds an observer seat.

Valtech Cardio, Ltd. is located in Or-Yehuda, Israel.

www.valtechcardio.com

NGN Capital co-led an initial investment of a targeted $30 million Series A financing of Vivaldi Biosciences, Inc.

Vivaldi is an emerging flu vaccine company developing unique live attenuated vaccines for seasonal and pandemic influenza.

Dr. Peter Johann and Dr. Georg Nebgen hold seats on the board of directors. Dr. Ivica Cerina holds an observer seat.

Vivaldi is based in San Francisco, CA.

www.vivaldibiosciences.com